Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model

Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib

(2016) Neil J Parrott et al.   AAPS Journal

Can an Acidic Beverage Reduce Interactions Between Proton Pump Inhibitors and Erlotinib?

(2016) David Planchard   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic drug monitoring and tyrosine kinase inhibitors

(2016) Pauline Herviou et al.   Oncology Letters

Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals

(2015) Heidemarie Kletzl et al.   ANTI-CANCER DRUGS

Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer

(2015) Michael P. Chu et al.   Clinical Lung Cancer

Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective

(2014) Roelof W F van Leeuwen et al.   LANCET ONCOLOGY

P-0042 * PHARMACOKINETICS OF ERLOTINIB AND ITS MAIN METABOLITE OSI420 IN ADVANCED PANCREATIC CANCER PATIENTS WHEN COMBINED WITH ESCALATING DOSES OF CAPECITABINE

(2013) A. Sahmanovic et al.   ANNALS OF ONCOLOGY

PBPK models for the prediction of in vivo performance of oral dosage forms

(2013) Edmund S. Kostewicz et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme

(2013) David M. Peereboom et al.   NEURO-ONCOLOGY

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

(2013) Nienke A. G. Lankheet et al.   THERAPEUTIC DRUG MONITORING

Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies

(2012) Bo Gao et al.   JOURNAL OF CLINICAL ONCOLOGY

HMDB 3.0—The Human Metabolome Database in 2013

(2012) David S. Wishart et al.   NUCLEIC ACIDS RESEARCH

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function

(2011) Cindy L. O’Bryant et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 1: Oral solutions

(2011) Kirstin Thelen et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Evolution of a Detailed Physiological Model to Simulate the Gastrointestinal Transit and Absorption Process in Humans, Part II: Extension to Describe Performance of Solid Dosage Forms

(2011) Kirstin Thelen et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Erlotinib and pantoprazole: a relevant interaction or not?

(2010) Rob Ter Heine et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)

(2010) Eric H. Kraut et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion

(2010) K. Sandy Pang et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Predicting Pharmacokinetics of Drugs Using Physiologically Based Modeling—Application to Food Effects

(2009) N. Parrott et al.   AAPS Journal

Modelling and PBPK Simulation in Drug Discovery

(2009) Hannah M. Jones et al.   AAPS Journal

A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin

(2009) M. Ranson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients

(2007) E. Van Cutsem et al.   ANNALS OF ONCOLOGY